Literature DB >> 23430681

[Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].

D Pauleikhoff1, B Bertram, F G Holz, B Kirchhof, U Bartz-Schmidt, N Bornfeld, M Bresgen, N Eter, W Friedrichs, H Heimann, H Helbig, H Hörauf, A Kampik, K D Lemmen, J Roider, F Ziemssen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23430681     DOI： 10.1055/s-0032-1328113

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN： 0023-2165            Impact factor:   0.700


× No keyword cloud information.
  9 in total

1.  [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].

Authors: 
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

2.  [Reasons for delayed and discontinued therapy in age-related macular degeneration].

Authors:  M W M Wintergerst; J Bouws; J Loss; B Heimes; D Pauleikhoff; F G Holz; R P Finger
Journal:  Ophthalmologe       Date:  2018-12       Impact factor: 1.059

3.  [Differential diagnosis and therapy of pigment epithelial detachment].

Authors:  M A Gamulescu; H Helbig; J Wachtlin
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

4.  [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

Authors:  D Pauleikhoff; B Bertram; D Claessens
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

5.  [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration].

Authors:  M Ziegler; B Heimes; B Book; M Dietzel; M Zeimer; G Spital; M Gutfleisch; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

6.  Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD.

Authors:  Claus von der Burchard; Felix Treumer; Christoph Ehlken; Stefan Koinzer; Konstantine Purtskhvanidze; Jan Tode; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-18       Impact factor: 3.117

7.  [Visual acuity in anti-VEGF therapy for AMD : Can specific characteristics in the SD-OCT help?]

Authors:  B Book; M Ziegler; B Heimes; M Gutfleisch; G Spital; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2017-01       Impact factor: 1.059

8.  [Serous vascularized pigment epithelial detachment in exudative AMD. Morphological typing and risk of tears in the RPE].

Authors:  B Lehmann; B Heimes; M Gutfleisch; G Spital; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

9.  [Health services for patients with neovascular age-related macular degeneration in Germany].

Authors:  R P Finger; F G Holz
Journal:  Ophthalmologe       Date:  2014-05       Impact factor: 1.059
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.